{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=68",
    "query": {
      "condition": "Recurrent Neoplasm",
      "page": 68
    },
    "page_size": 10
  },
  "pagination": {
    "page": 68,
    "page_size": 10,
    "total_count": 9120,
    "total_pages": 912,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=69&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=67&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T23:17:29.557Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04406272",
      "title": "VB-111 in Surgically Accessible Recurrent/Progressive GBM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "VB11",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-08-01",
      "completion_date": "2024-08-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04406272"
    },
    {
      "nct_id": "NCT04387422",
      "title": "Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Experimental hyperglycemia",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-08-12",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04387422"
    },
    {
      "nct_id": "NCT01574222",
      "title": "A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "autologous dendritic cell adenovirus CCL21 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2011-10-01",
      "completion_date": "2017-03-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 1,
      "location_summary": "West Los Angeles, California",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01574222"
    },
    {
      "nct_id": "NCT06160206",
      "title": "Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Recurrent WHO Grade 4 Glioma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Retifanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2024-10-02",
      "completion_date": "2030-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06160206"
    },
    {
      "nct_id": "NCT01156584",
      "title": "A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Oligoastrocytoma"
      ],
      "interventions": [
        {
          "name": "Toca 511 vector",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Toca FC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Tocagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2010-07",
      "completion_date": "2016-08-18",
      "has_results": false,
      "last_update_posted_date": "2018-05-21",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156584"
    },
    {
      "nct_id": "NCT00939484",
      "title": "Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2009-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-02-25",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939484"
    },
    {
      "nct_id": "NCT01590147",
      "title": "Supportive Intervention Programs Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fatigue",
        "Nausea and Vomiting",
        "Pain",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Stage I-IVB Colon Cancer",
        "Stage I-IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Yoga therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "OTHER"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "educational intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Wake Forest University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2011-06",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590147"
    },
    {
      "nct_id": "NCT06630338",
      "title": "Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Tumor",
        "Recurrent Brain Tumor",
        "Brain Neoplasm",
        "Recurrent Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Non-Interventional Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2027-06-01",
      "completion_date": "2034-06-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630338"
    },
    {
      "nct_id": "NCT03109158",
      "title": "NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell of Head and Neck"
      ],
      "interventions": [
        {
          "name": "NC-6004",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NanoCarrier Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-03-01",
      "completion_date": "2019-03-01",
      "has_results": false,
      "last_update_posted_date": "2019-04-29",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03109158"
    },
    {
      "nct_id": "NCT00003316",
      "title": "Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-04-11",
      "last_synced_at": "2026-11-08T23:17:29.557Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003316"
    }
  ]
}